HC Wainwright Has Negative View of uniQure FY2024 Earnings

uniQure (NASDAQ:QURE) – HC Wainwright lowered their FY2024 EPS estimates for shares of uniQure in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings per share of ($4.17) for the year, down from their previous forecast of ($4.16). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS and FY2028 earnings at $16.97 EPS.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.

Several other brokerages have also recently commented on QURE. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday, December 11th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their price target for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, Mizuho lifted their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

uniQure Trading Down 3.0 %

NASDAQ QURE opened at $15.32 on Wednesday. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The business’s 50-day moving average price is $13.31 and its two-hundred day moving average price is $8.84.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its stake in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares during the last quarter. Sanders Morris Harris LLC grew its stake in shares of uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after acquiring an additional 34,034 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $88,000. Franklin Resources Inc. bought a new position in shares of uniQure during the third quarter valued at about $7,360,000. Finally, Geode Capital Management LLC lifted its position in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.